Get the Stockscreener App
8.27
1.66%
-0.14
Xencor Inc stock is traded at $8.27, with a volume of 1.46M.
It is down -1.66% in the last 24 hours and up +9.25% over the past month.
Xencor Inc a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab, and XmAb657. The group earns its revenue from collaboration agreements, product licensing agreements, and technology licensing agreements.
See More
Previous Close:
$8.41
Open:
$8.56
24h Volume:
1.46M
Relative Volume:
1.57
Market Cap:
$693.20M
Revenue:
$133.62M
Net Income/Loss:
$-177.37M
P/E Ratio:
-2.8616
EPS:
-2.89
Net Cash Flow:
$23.50M
1W Performance:
-0.48%
1M Performance:
+9.25%
6M Performance:
-65.95%
1Y Performance:
-58.84%
1-Day Range:
$8.18
$8.56
1-Week Range:
$8.01
$8.73
52-Week Range:
$7.16
$27.24
Xencor Inc Stock (XNCR) Company Profile
Name
Xencor Inc
Sector
Industry
Phone
626-305-5900
Address
465 N. HALSTEAD ST., PASADENA, CA
Compare XNCR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
XNCR
Xencor Inc
|
8.27 | 693.20M | 133.62M | -177.37M | 23.50M | -2.89 |
|
VRTX
Vertex Pharmaceuticals Inc
|
450.27 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
522.27 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.00 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
568.06 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
266.80 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Xencor Inc Stock (XNCR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-21-25 | Initiated | William Blair | Outperform |
| Dec-12-24 | Initiated | Wells Fargo | Overweight |
| Dec-02-24 | Upgrade | Piper Sandler | Neutral → Overweight |
| Apr-16-24 | Reiterated | BTIG Research | Buy |
| Feb-28-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| May-19-23 | Initiated | BofA Securities | Buy |
| Dec-06-22 | Initiated | Cowen | Outperform |
| Oct-13-22 | Upgrade | Raymond James | Outperform → Strong Buy |
| Sep-21-22 | Initiated | JP Morgan | Overweight |
| Jul-06-22 | Resumed | Canaccord Genuity | Buy |
| Feb-11-22 | Initiated | BMO Capital Markets | Outperform |
| Jan-21-22 | Initiated | SMBC Nikko | Outperform |
| Dec-15-21 | Initiated | H.C. Wainwright | Buy |
| Oct-15-21 | Resumed | BTIG Research | Buy |
| Feb-24-21 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Mar-04-20 | Initiated | Barclays | Underweight |
| Feb-25-20 | Upgrade | Guggenheim | Neutral → Buy |
| Jan-30-20 | Initiated | RBC Capital Mkts | Outperform |
| Nov-20-19 | Resumed | Guggenheim | Neutral |
| Aug-07-19 | Downgrade | Guggenheim | Buy → Neutral |
| Aug-07-19 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jun-13-19 | Initiated | Mizuho | Buy |
| Apr-12-19 | Initiated | Guggenheim | Buy |
| Mar-27-19 | Initiated | Berenberg | Buy |
| Mar-15-19 | Initiated | Raymond James | Outperform |
| Sep-10-18 | Resumed | BTIG Research | Buy |
| Mar-28-18 | Resumed | Leerink Partners | Outperform |
| Mar-02-17 | Initiated | Instinet | Neutral |
| Mar-02-17 | Reiterated | Wedbush | Outperform |
| Oct-04-16 | Initiated | Piper Jaffray | Overweight |
| Dec-22-15 | Initiated | Canaccord Genuity | Buy |
| Aug-05-15 | Reiterated | MLV & Co | Buy |
| Feb-12-15 | Reiterated | Oppenheimer | Outperform |
| Jan-28-15 | Reiterated | MLV & Co | Buy |
| Jul-11-14 | Initiated | Oppenheimer | Outperform |
View All
Xencor Inc Stock (XNCR) Latest News
Closing Figures Unveiled: Xencor Inc (XNCR) Drop -8.18, Closes at 8.31 - DWinneX
Rhumbline Advisers Has $1.74 Million Stake in Xencor, Inc. (NASDAQ:XNCR) - Defense World
Xencor (NASDAQ:XNCR) Shares Down 5.7% on Insider Selling - Defense World
(XNCR) On The My Stocks Page - news.stocktradersdaily.com
Xencor director Montgomery sells shares worth $20,422 - Investing.com
Xencor director Gustafson sells shares worth $27,595 - Investing.com
Xencor Holds Annual Stockholders Meeting on June 12 - TipRanks
Xencor (NASDAQ:XNCR) Trading Up 6.3%Should You Buy? - MarketBeat
USPTO Tells Fed. Circ. Not To Review Ruling In Xencor Case - Law360
Xencor, Inc. (NASDAQ:XNCR) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Xencor, Inc. (NASDAQ:XNCR) Shares Purchased by California State Teachers Retirement System - Defense World
Bank of America Corp DE Sells 585,930 Shares of Xencor, Inc. (NASDAQ:XNCR) - Defense World
27,491 Shares in Xencor, Inc. (NASDAQ:XNCR) Acquired by Wellington Management Group LLP - Defense World
Xencor, Inc. (NASDAQ:XNCR) Receives Average Recommendation of “Moderate Buy” from Brokerages - Defense World
Xencor, Inc. (NASDAQ:XNCR) Shares Sold by Squarepoint Ops LLC - Defense World
When (XNCR) Moves Investors should Listen - news.stocktradersdaily.com
Xencor Inc (NASDAQ: XNCR) Jumps 2.45%: What Could Be On The Way Going Forward? - Stocksregister
Xencor, Inc. (XNCR) Stock Analysis: Exploring a Biotechnology Innovator with 264.58% Potential Upside - DirectorsTalk Interviews
Xencor’s SWOT analysis: biotech stock faces pivotal year amid pipeline progress - Investing.com Nigeria
Xencor’s SWOT analysis: biotech stock faces pivotal year amid pipeline progress By Investing.com - Investing.com South Africa
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Has $929,000 Holdings in Xencor, Inc. (NASDAQ:XNCR) - Defense World
Where are the Opportunities in (XNCR) - news.stocktradersdaily.com
BNP Paribas Financial Markets Purchases 3,171 Shares of Xencor, Inc. (NASDAQ:XNCR) - Defense World
Xencor, Inc. (NASDAQ:XNCR) Holdings Lowered by Jane Street Group LLC - Defense World
Deutsche Bank AG Buys 20,128 Shares of Xencor, Inc. (NASDAQ:XNCR) - Defense World
Xencor, Inc. (XNCR) Stock Analysis: Exploring a Potential 266% Upside in Biotech Investments - DirectorsTalk Interviews
Ameriprise Financial Inc. Has $6.72 Million Stake in Xencor, Inc. (NASDAQ:XNCR) - Defense World
Life Sciences Companies Have New Avenue to Challenge Patent Applications After Federal Court Ruling - JD Supra
Xencor, Inc. (NASDAQ:XNCR) Position Boosted by Comerica Bank - Defense World
Xencor Inc. Reports Revenue Growth Amidst Ongoing R&D Investments - TipRanks
Northern Trust Corp Increases Holdings in Xencor, Inc. (NASDAQ:XNCR) - Defense World
Investor Network: Xencor, Inc. to Host Earnings Call - ACCESS Newswire
Xencor, Inc. (NASDAQ:XNCR) Given Average Recommendation of “Moderate Buy” by Brokerages - Defense World
Cancer Centers Want Fed. Circ. To Rehear Antibody IP Fight - Law360
Leerink Partnrs Has Bearish Forecast for Xencor Q2 Earnings - Defense World
Wedbush Comments on Xencor’s Q2 Earnings (NASDAQ:XNCR) - Defense World
Research Analysts Set Expectations for Xencor Q2 Earnings - Defense World
JPMorgan cuts Xencor stock price target to $20, keeps overweight rating - Investing.com Nigeria
Q4 Earnings Forecast for Xencor Issued By William Blair - Defense World
What is Wedbush’s Estimate for Xencor Q4 Earnings? - Defense World
Barclays Issues Pessimistic Forecast for Xencor (NASDAQ:XNCR) Stock Price - Defense World
Analysts Offer Insights on Healthcare Companies: Ardent Health Partners, Inc. (ARDT), Xencor (XNCR) and LivaNova (LIVN) - The Globe and Mail
Xencor Inc earnings missed by $0.04, revenue topped estimates - Investing.com Nigeria
Xencor (XNCR) Analyst Rating Update: Price Target Slashed by Bar - GuruFocus
Xencor (XNCR) Analyst Rating Update: Price Target Slashed by Barclays | XNCR Stock News - GuruFocus
JPMorgan cuts Xencor stock price target to $20, keeps overweight rating By Investing.com - Investing.com South Africa
Xencor Reports First Quarter 2025 Financial Results - BioSpace
Xencor: Q1 Earnings Snapshot - MySA
Xencor (XNCR) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
Xencor Inc Stock (XNCR) Financials Data
Revenue
Net Income
Cash Flow
EPS
Xencor Inc Stock (XNCR) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| GUSTAFSON KURT A | Director |
Jun 16 '25 |
Sale |
9.22 |
2,993 |
27,595 |
20,183 |
| GORMAN KEVIN CHARLES | Director |
Jun 16 '25 |
Sale |
9.22 |
3,173 |
29,255 |
18,905 |
| Feigal Ellen | Director |
Jun 16 '25 |
Sale |
9.22 |
2,993 |
27,595 |
19,183 |
| RANIERI RICHARD J | Director |
Jun 16 '25 |
Sale |
9.22 |
2,993 |
27,595 |
19,183 |
0.29%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):